Lisdexamfetamine Dimesylate Capsules Solicitation
Closed Solicitation Posted
- Solicitation number
- SPE2D2-26-R-0004
- Agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency Troop Support Medical Supply Chain seeks offers for Lisdexamfetamine Dimesylate capsules across multiple strengths (10 MG through 70 MG) in 90-count and 100-count bottles, with the current proposal deadline of July 28, 2026. Amendment 0002, posted July 14, extended the deadline from the originally posted June 2 date; offerors must acknowledge receipt of both Amendment 0001 and Amendment 0002 prior to closing.
This is a firm-fixed-price requirements contract with a one-year base period plus four option years. Estimated annual quantities range from 71 to 17,426 bottles depending on product variant. Place of performance is Philadelphia, Pennsylvania (DLA Troop Support Medical Supply Chain administrative location), with distribution to Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons facilities. The NAICS code is 325412, Pharmaceutical Preparation Manufacturing; PSC is 6505, Drugs and Biologicals.
The solicitation uses Lowest Price Technically Acceptable methodology. Offerors must comply with FDA current Good Manufacturing Practices, provide National Drug Codes, and maintain unit-of-use packaging with GS1-128 barcode labeling. Orders are transmitted electronically via the Defense Logistics Agency Internet Bid Board System. Contract awards are made to pharmaceutical prime vendors (AmerisourceBergen, Cardinal Health, DMS Pharmaceutical Group, and McKesson) for distribution; contractors receive payments from prime vendors rather than directly from the Government. Large business offerors must submit subcontracting plans. Contract price becomes effective no more than 60 days after award, with performance commencing 45 days after award. Quarterly sales reports and a 0.5 percent cost recovery fee are required.
Notice text
3 versions
Update #3 · Latest ·
Amendment 0002 has been issued to extend the solicitation to have offers due on 7/28/2026.
Update #2 ·
Amendment 0001 has been issued to extend the solicitation to have offers due on 7/14/2026.
Update #1 ·
Solicitation for Lisdexamfetamine Dimseylate SPE2D2-26-D-0004.
Files
| File | Type | Posted |
|---|---|---|
| SF30_SPE2D226R00040002.PDF | ||
| SF30_SPE2D226R00040001.PDF | ||
| SPE2D2-26-R-0004 - Lisdexamfetamine Solicitation.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Solicitation | |
| Lisdexamfetamine Dimesylate Capsules | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Methylphenidate ER | Medical Supply Chain | No set-aside | |
| Epinephrine Injector | Medical Supply Chain | No set-aside | |
| 6505--Imatinib Tablets | National Acquisition Center | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity